Effects of AAT treatment of donor, recipient, or both on GVHD and posttransplant outcome. (A) Treatment scheme for both donor (blue) and recipient (red). (B) Results with C3H.SW (H-2^b) donors and C57BL/6 (H 2^bc) recipients (minor mismatch) and (C) results with C57BL/6 (H-2^bK^b) donors, and Balb/c (H-2^d K^d) recipients (major mismatch). Either donor (AAT/albumin) or recipient (albumin/AAT), both (AAT/AAT) or neither (albumin/albumin) were treated with AAT; albumin served as control. Left panels show survival; middle and right panels show body weight changes and GVHD scores (n = 12 for each transplant condition). (D) Changes in cytokine levels in donor marrow and spleen following AAT treatment relative to albumin controls (determined by RT-PCR; n = 7 mice per group). Results are expressed as mean ± SEM (log2) from pooled tissue extracts (marrow and spleen preparations). Ω indicates P values of at least = .01 when compared with albumin-treated control cells.